MARKETSnap
  • Market Snapshots
    • Gainers & Losers
    • Most Active & More
    • 52-Week High/Low
    • Dividends
    • P/E Ratios
      • Large Caps
      • Absolute
      • Total Market PE
    • Stocks Performance
      • Large Caps
      • Absolute
    • Industries Performance
      • Industry
      • Sector
  • Analyze Stock
    • Analyze a stockAnalyze BDX →
    • FindStock Picks / Stock Screener
    • Value · BDXIntrinsic Value Calculator
    • Invest · BDXInvestment Case
    • Hold · BDX5-Year Outlook
  • Learn
  • Calendar
  • Investment Compounding
    Calculator
  • Investing Philosophy
  • More
    • Charts
    • Commodities
    • Currencies
    • Economic Indicators
      • Inflation
      • Consumer Sentiment
      • Recession Probability
      • Treasury Rates
      • GDP
BDX stock logo

BDX

Becton, Dickinson and Company

$212.78
0.1
 (0.05%)
Exchange:  NYSE
Market Cap:  57.959B
Shares Outstanding:  278.486M
Delayed data
Overview
Earnings
Financials
Valuation
Chart

About The Company

Sector:  HealthcareView sector performance
Industry:  Medical – Instruments & SuppliesView industry performance
   
CEO:  Thomas E. Polen Jr.
Full Time Employees:  60000
Address: 
1 Becton Drive
Franklin Lakes
NJ
07417-1880
US
Website:  https://www.bd.com
Operating globally, Becton, Dickinson and Company (BD) is a prominent enterprise focused on the development, manufacturing, and distribution of a broad spectrum of medical technology. This includes essential medical supplies, sophisticated devices, advanced laboratory equipment, and critical diagnostic products. Its extensive customer base comprises healthcare providers, clinical institutions, medical researchers, pharmaceutical firms, and the general public around the world. The BD Medical division delivers a comprehensive suite of products primarily focused on medication management and drug delivery. This encompasses a variety of intravenous (IV) access solutions, such as peripheral and advanced catheters, central lines, acute dialysis catheters, and related vascular care items including needle-free connectors and closed-system drug transfer devices. It also provides essential injection equipment like hypodermic syringes, needles, anesthesia trays, enteral syringes, and sharps disposal systems. Additionally, this segment develops integrated systems for IV medication and infusion therapy, medication compounding workflow, automated dispensing, and supply chain optimization. Specialized products for diabetes management, including pen needles, along with prefillable drug delivery systems, are also key offerings. BD Life Sciences focuses on diagnostic and research tools, offering products for specimen and blood collection. This segment supplies automated systems for culturing blood and tuberculosis, molecular testing, microorganism identification, and drug susceptibility analysis. It also provides liquid-based cytology systems, rapid diagnostic assays, microbiology laboratory automation, and plated media. Furthermore, it offers advanced solutions for cell analysis, including fluorescence-activated cell sorters and analyzers, antibodies, kits, and reagent systems. These are crucial for single-cell gene expression analysis, as well as for clinical oncology, immunological, and transplantation diagnostics and monitoring. Finally, the BD Interventional segment delivers specialized products for surgical and interventional procedures. Its portfolio includes solutions for hernia and soft tissue repair, biological and bioresorbable grafts, and biosurgery, alongside other surgical products. This segment also addresses surgical infection prevention, provides a range of surgical and laparoscopic instrumentation, offers peripheral intervention products, and supplies urology and critical care devices. Established in 1897, the company maintains its headquarters in Franklin Lakes, New Jersey.

Click to read more…

Revenue Segmentation

Revenue by type

Revenue by region

Log in to continue

Log in to see the complete revenue and geographic breakdown.

Log in — it's free

Industry Peers

TICKERCOMPANYMKT CAPP/EFWD P/EROIC
BDBDX logoBDXBecton, Dickinson and Company58.0B52.516.84.1%
RMRMD logoRMDResMed Inc.33.1B21.821.221.2%
MDMDLN logoMDLNMedline Inc.32.5B58.923.93.7%
WSWST logoWSTWest Pharmaceutical Services, Inc.27.2B46.441.117.9%
SOSOLV logoSOLVSolventum Corporation14.4B10011.716.6%
BABAX logoBAXBaxter International Inc.13.1B—12.0-1.3%

EPS

Historical EPS and analyst estimates in one chart. Log in for the full interactive view and links to detailed estimates.

Log in to continue

Log in for the full EPS chart and links to analyst estimates.

Log in — it's free
View full analyst estimates

Earnings Call

Full text

Earnings transcript

Read the complete earnings call transcript.

AI summary

Key takeaways

Short, structured highlights from the call so you can focus on what matters.

2026/11/05 — 4 quarter 2026

Log in to continue

Log in to read the full transcript and AI-generated earnings summaries.

Log in — it's free
Income Statement
Balance Sheet
Cash Flow Statement
Analyst Estimates

Income Statement

Year202420252026
Revenue20,178,00021,839,00019,457,000
Gross Profit9,125,0009,924,0009,214,000
EBITDA4,819,0004,957,0004,607,000
Operating Income2,397,0002,578,0002,256,000
Net Income1,705,0001,678,0001,146,000

Log in to continue

Log in to see the income statement and 10 historical years.

Log in — it's free

(* All numbers are in thousands)

Balance Sheet

Year202420252026
Total Assets57,286,00055,325,00050,791,000
Total Liabilities31,397,00029,936,00016,566,000
Total Stockholders Equity25,889,00025,390,00050,791,000
Total Debt20,919,00019,181,00014,366,000
Cash and Cash Equivalents1,717,000851,000725,000

Log in to continue

Log in to see the balance sheet and 10 historical years.

Log in — it's free

(* All numbers are in thousands)

Cash Flow Statement

Year202420252026
Operating Cash Flow3,798,0003,430,0003,366,000
Capital Expenditure-725,000-760,000-672,000
Free Cash Flow3,072,0002,670,0002,694,000
Net Income1,705,0001,678,0001,145,000
Net Change in Cash375,000-1,005,000233,000

Log in to continue

Log in to see the cash flow statement and 10 historical years.

Log in — it's free

(* All numbers are in thousands)

Analyst Estimates

Fiscal Year2031Research AccessResearch AccessResearch AccessResearch Access
Estimated Revenue (Low)22,669,467.782Research AccessResearch AccessResearch AccessResearch Access
Estimated Revenue (High)23,478,873.852Research AccessResearch AccessResearch AccessResearch Access
Estimated Revenue (Avg)22,905,000Research AccessResearch AccessResearch AccessResearch Access
Estimated Ebitda (Low)7,527,327.625Research AccessResearch AccessResearch AccessResearch Access
Estimated Ebitda (High)7,789,798.819Research AccessResearch AccessResearch AccessResearch Access
Estimated Ebitda (Avg)7,603,705.841Research AccessResearch AccessResearch AccessResearch Access
Estimated Net Income (Low)4,811,348.002Research AccessResearch AccessResearch AccessResearch Access
Estimated Net Income (High)5,035,369.187Research AccessResearch AccessResearch AccessResearch Access
Estimated Net Income (Avg)4,876,537.397Research AccessResearch AccessResearch AccessResearch Access
Estimated SGA Expense (Low)5,579,709.952Research AccessResearch AccessResearch AccessResearch Access
Estimated SGA Expense (High)5,778,931.704Research AccessResearch AccessResearch AccessResearch Access
Estimated SGA Expense (Avg)5,637,682.264Research AccessResearch AccessResearch AccessResearch Access
Estimated EPS (Avg)17.420Research AccessResearch AccessResearch AccessResearch Access
Estimated EPS (High)17.990Research AccessResearch AccessResearch AccessResearch Access
Estimated EPS (Low)17.190Research AccessResearch AccessResearch AccessResearch Access
Number of Analysts (Estimated Revenue)3Research AccessResearch AccessResearch AccessResearch Access
Number of Analysts (Estimated EPS)1Research AccessResearch AccessResearch AccessResearch Access

Log in to continue

Log in with Research Access to see up to 5 years of analyst estimates.

Create a free account

(* All numbers are in thousands)

Current Key Metrics

?Revenue
 (TTM)
: 
20.178B  ?P/S
 (TTM)
: 
2.94
?Net Income
 (TTM)
: 
1.705B  ?P/E
 (TTM)
: 
52.54
?Enterprise Value
 (TTM)
: 
75.009B  ?EV/FCF
 (TTM)
: 
27.1
?Dividend Yield
 (TTM)
: 
1.82%  ?Payout Ratio
 (TTM)
: 
152.97%
?ROE
 (TTM)
: 
4.65%  ?ROIC
 (TTM)
: 
4.05%
?Net Debt
 (TTM)
: 
17.928B  ?Debt/Equity
 (TTM)
: 
0.66
?P/B
 (TTM)
: 
2.41  ?Current Ratio
 (TTM)
: 
0.87

Log in to continue

Log in to see all key valuation metrics and ratios for this symbol.

Log in — it's free

Forward P/E Ratios

?

Forward P/E (Avg EPS estimate) — log in with Research Access for high/low estimates and the interactive table.

Forward P/E 1YResearch AccessResearch AccessResearch AccessResearch Access
16.79Research AccessResearch AccessResearch AccessResearch Access

Log in to continue

Log in with Research Access for forward P/E high/low estimates and the full multi-year table.

Create a free account

SWOT Analysis

🔒 You are currently logged out

Login

It's free

At what price to buy it? -
Intrinsic Value Calculator

Based on current fundamentals and analyst forecasts, MarketSnap estimates BDX intrinsic value between $200.68 – $250.53 per share. This depends on revenue growth, margins, and discount rate.

This is an automatic estimate. The most reliable way to know fair value for your own assumptions is to run the calculator below.


Calculate BDX Intrinsic Value

Common questions about BDX valuation

Is Becton, Dickinson and Company (BDX) overvalued or undervalued right now?

MarketSnap estimates intrinsic value for Becton, Dickinson and Company (BDX) using its proprietary valuation methodology, which incorporates discounted cash flow (DCF) analysis together with long-term earnings and fundamentals assumptions. By comparing intrinsic value to the current market price, long-term investors can see whether the stock screens as potentially overvalued, fairly valued, or undervalued today.

Is BDX a buy, hold, or sell for long-term investors?

MarketSnap does not give one-word “buy” or “sell” calls. Instead, it shows whether BDX trades at a premium or discount to its estimated intrinsic value, how sensitive that value is to growth and margin assumptions, and how the stock fits into a diversified, long-term portfolio so investors can make their own buy, hold, or sell decision.

What is BDX’s P/E ratio?

You can see BDX’s trailing P/E (TTM) and forward P/E estimates in the Current Key Metrics and Forward P/E Ratios sections above. The P/E ratio compares the current share price to earnings per share and helps investors gauge valuation relative to earnings.

How is intrinsic value calculated for BDX?

MarketSnap uses its own valuation framework—not a generic spreadsheet DCF alone. Future cash flows and earnings are projected, discounted, and combined with MarketSnap’s methodology so intrinsic value reflects fundamentals and long-term assumptions. You can run your own inputs and see the result using the Intrinsic Value Calculator above.

Is BDX a good long-term investment?

Whether BDX fits a long-term portfolio depends on your assumptions about growth, margins, and risk. MarketSnap provides the metrics, intrinsic value calculator, and SWOT context so you can form your own view rather than rely on a single buy/sell rating.

Research tools for Becton, Dickinson and Company

  • Becton, Dickinson and Company intrinsic value calculatorEstimate what the business is worth
  • Becton, Dickinson and Company 5-year outlookWhat has to go right, and what could go wrong
BDX

1-day price chart preview. Log in for 1W through 5Y ranges and period tabs.

Daily snapshot

0.05
MarketSnap

Trading Metrics:

Open: 212.71   Previous Close: 212.68
Day Low: 211.72   Day High: 216.51
Year Low: 140.11   Year High: 220.36
Price Avg 50: 193.75   Price Avg 200: 169.57
Volume: 1.961M   Average Volume: 1.818M

Log in to continue

Log in for multi-period charts (1W–5Y), period tabs, and the same layout as members.

Log in — it's free
See in Nexus

Relevant news

BD Named to TIME's 2027 List of America's Top Manufacturers
19-11-2026 06:00
BD Named to TIME's 2027 List of America's Top Manufacturers
3 Stocks in Focus That Hiked Dividends Amid Ongoing Market Volatility
06-11-2026 09:36
3 Stocks in Focus That Hiked Dividends Amid Ongoing Market Volatility
Becton, Dickinson and Company (BDX) Q4 2026 Earnings Call Transcript
05-11-2026 14:14
Becton, Dickinson and Company (BDX) Q4 2026 Earnings Call Transcript
BDX Stock Down in Pre-Market Despite Q4 Earnings & Revenue Beat
05-11-2026 13:46
BDX Stock Down in Pre-Market Despite Q4 Earnings & Revenue Beat
BD Reports Fourth Quarter and Full Year Fiscal 2026 Financial Results
05-11-2026 06:30
BD Reports Fourth Quarter and Full Year Fiscal 2026 Financial Results
BD Board Increases Dividend for 55th Consecutive Year, Authorizes 10 Million Additional Share Repurchases
05-11-2026 06:25
BD Board Increases Dividend for 55th Consecutive Year, Authorizes 10 Million Additional Share Repurchases

DISCLAIMER: The stock market data provided on this website is for informational purposes only and is not intended for trading purposes. While we strive to provide accurate and timely information, we cannot guarantee that the information is accurate at the moment it is received or that it will continue to be accurate in the future. We are not responsible for any actions taken based on the information provided on this website. Always consult with a licensed financial professional before making any investment decisions.
Terms of Service

Copyright © 2025 MarketSnap. All rights reserved.

Pricing

How MarketSnap works

What’s new

Contact Us

Privacy Policy

Cookie Policy

Terms of Service

Hover Image
MARKETSnap

Market

🇺🇸 United States

Language

    • Gainers & Losers
    • Most Active & More
    • 52-Week High/Low
    • Dividends
      • Large Caps
      • Absolute
      • Total Market PE
      • Large Caps
      • Absolute
      • Industry
      • Sector
    • Analyze a stockAnalyze BDX →
    • FindStock Picks / Stock Screener
    • Value · BDXIntrinsic Value Calculator
    • Invest · BDXInvestment Case
    • Hold · BDX5-Year Outlook
  • Learn
  • Calendar
  • Investment Compounding Calculator
    • Charts
    • Commodities
    • Currencies
      • Inflation
      • Consumer Sentiment
      • Recession Probability
      • Treasury Rates
      • GDP
  • Investing Philosophy
  • Nexus
    • Recent Activity
      • Overview
      • My Valuations
      • My Investment Journal
      • Watchlists & Portfolio
    • Plans
    • Settings
    • Public profile ↗
  • Log in
  • Log out

Media

Watch Listen Read
Ask MarketSnap AI

MarketSnap AI Assistant

Uses MarketSnap data and this page

Ready

🔒 You are currently logged out

Login

It's free

MarketSnap Assistant · Tips
    MarketSnap

    Welcome to MarketSnap

    The AI-powered workspace for stock pickers.

    Continue with Google Continue with email

    Already a member? Sign in

    Find stocks·Value them·Build the case·Journal decisions·Track what changes

    Free to join. No card needed. Privacy Policy

    Create your free MarketSnap account Continue with Google
    Chat with us MarketSnap support · account, plans, settings, help
    How MarketSnap works

    The conversation above goes to the MarketSnap team with your message. We reply by e-mail.